Citations 2
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
Fervenza, Fernando C. , Hao, ChuanâMing , Kirsztajn, Gianna M., Gesualdo, Loreto, Pisani, Antonio, Roccatello, D, Bomback, Andrew S., Rae, Julie, Barmaki, Farima, Berisha, Eriola, Schindler, Thomas, Garg, Jay P, Malvar, Ana , Fervenza, Fernando C , Hou, Fan Fan , Kirsztajn, Gianna Mastroianni , Gesualdo, Loreto , Hryszko, Tomasz , Pisani, Antonio, Bomback, Andrew S. , Rae, Julie , Berisha, Eriola, Schindler, Thomas Hellmut , Omachi, Theodore A. , Garg, Jay P, Malvar, Ana
New England Journal of Medicine | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
MAJESTY: A Phase 3, Randomized, Open-Label, Active Comparator-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy
Appel, Gerald B., Prot, Sylvie, Berisha, Eriola, Khatri, Leena, Parsons, T. M. C., Spinks, E. Ann, Boston, Heather, Riboulet, William, Han, Xiaoyan , Fervenza, Fernando C. , Gesualdo, Loreto , Kirsztajn, Gianna Mastroianni , Hou, Fan Fan , Berisha, Eriola, Chen, Debbie , Bomback, Andrew S.
Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available